US · BHC
Bausch Health Companies Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Laval, QC H7L 4A8
- Website
- bauschhealth.com
Price · as of 2025-12-31
$5.65
Market cap 2.2B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $62.72 | +1,010.09% |
| Intrinsic Value(DCF) | $9.88 | +74.87% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $6.29 | +11.38% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $55.58 | $78.60 | $141.18 | $3.71 | $61.87 |
| 2012 | $70.78 | $60.96 | $1,228.09 | $0.00 | $0.00 |
| 2013 | $141.37 | $104.53 | $4,848.41 | $0.00 | $0.00 |
| 2014 | $197.43 | $136.10 | $3,809.90 | $1.01 | $127.38 |
| 2015 | $69.55 | $123.21 | $2,173.00 | $0.00 | $0.00 |
| 2016 | $12.24 | $80.65 | $15.16 | $0.00 | $0.00 |
| 2017 | $15.38 | $95.11 | $0.24 | $6.50 | $0.00 |
| 2018 | $23.37 | $68.10 | $0.00 | $0.00 | $0.00 |
| 2019 | $20.96 | $68.55 | $0.00 | $0.00 | $0.00 |
| 2020 | $33.34 | $77.82 | $0.00 | $0.00 | $0.00 |
| 2021 | $22.32 | $65.02 | $0.00 | $0.00 | $0.00 |
| 2022 | $8.03 | $53.96 | $0.00 | $0.00 | $0.00 |
| 2023 | $9.23 | $61.18 | $0.00 | $0.00 | $0.00 |
| 2024 | $7.15 | $57.07 | $2.83 | $0.00 | $0.00 |
| 2025 | $5.95 | $62.72 | $15.13 | $0.00 | $6.29 |
AI valuation
Our deep-learning model estimates Bausch Health Companies Inc.'s (BHC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $62.72
- Current price
- $5.65
- AI upside
- +1,010.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.88
+74.87% upside
Graham-Dodd
—
— upside
Graham Formula
$6.29
+11.38% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BHC | Bausch Health Companies I… | $5.65 | 2.2B | +1,010% | +75% | — | +11% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| ALVO | Alvotech | $3.99 | 1.24B | +1,454% | +12% | — | — | -12.88 | -7.24 | 6.10 | -127.84 | — | -6.72 | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | -9.84% | -1.22 | -68.51% | 0.00% | 0.00% | 0.00% | 59.25 | -14.04 | 8.43 | -0.85 |
| ANIP | ANI Pharmaceuticals, Inc. | $73.90 | 1.66B | +30% | +2,956% | -42% | +164% | 19.26 | 2.79 | 1.71 | 7.47 | — | -1176.59 | 0.00% | 12.58% | 8.87% | 16.16% | 12.26% | 5.75% | 0.60 | 5.54 | 2.71 | 2.04 | 0.19 | -41923.00% | 4378.00% | 29356.00% | 12.28% | 0.67 | 25.00% | 0.08% | 1.50% | 30.03% | 13.93 | 8.36 | 1.75 | 2.25 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| CON | Concentra Group Holdings … | $23.96 | 3.07B | +123% | -60% | — | +21% | 17.38 | 7.64 | 1.39 | 8.47 | — | -2.26 | 28.34% | 96.50% | 7.99% | 51.66% | 111.32% | 6.42% | 1.37 | 19.10 | 1.14 | 1.00 | 1.12 | 0.00% | 1385.00% | 3283.00% | 9.30% | 0.83 | 19.29% | 0.00% | 0.00% | 43.58% | 1.66 | 12.39 | 1.60 | 4.00 |
| CPRX | Catalyst Pharmaceuticals,… | $23.08 | 2.84B | +180% | +200% | -28% | +106% | 13.63 | 3.06 | 4.96 | 6.90 | 48.24 | 3.55 | 85.19% | 43.77% | 36.39% | 25.49% | 84.59% | 21.92% | 0.00 | — | 6.08 | 5.68 | -2.20 | 2824.00% | 1978.00% | -1281.00% | 7.14% | 1.42 | 90.56% | 0.00% | 0.00% | 7.46% | 8.59 | 10.61 | 3.76 | 14.42 |
| HAE | Haemonetics Corporation | $63.32 | 2.96B | -0% | -52% | -67% | -37% | 21.15 | 4.32 | 2.61 | 12.54 | 47.48 | -14.83 | 57.21% | 16.30% | 12.32% | 18.83% | 10.54% | 7.22% | 1.49 | 22.76 | 1.62 | 0.88 | 2.58 | 4454.00% | 395.00% | 2338.00% | 4.02% | 0.31 | 8.56% | 0.00% | 0.00% | 6.34% | 20.13 | 31.34 | 3.28 | 2.54 |
| HCM | HUTCHMED (China) Limited | $14.33 | 2.59B | +159% | -38% | -61% | — | 74.95 | 3.72 | 4.49 | 147.56 | — | 3.74 | 44.64% | -6.94% | 5.99% | 5.06% | 131.28% | 2.95% | 0.12 | -15.22 | 2.83 | 2.67 | -4.55 | -6333.00% | -2480.00% | -10934.00% | -0.62% | 0.00 | 62.24% | 0.00% | 0.00% | 1.28% | -47.63 | -119.38 | 3.30 | 3.49 |
| MLYS | Mineralys Therapeutics, I… | $29.26 | 1.94B | — | — | — | — | -2.87 | 2.67 | — | -1.62 | -3.42 | 2.67 | 0.00% | — | — | -82.24% | 16423.64% | -77.72% | 0.00 | — | 14.02 | 13.53 | 0.59 | 8392.00% | — | 10501.00% | -32.59% | -11.36 | 14204.87% | 0.00% | 0.00% | 12.69% | -1.62 | -1.88 | — | 16.89 |
| PRGO | Perrigo Company plc | $13.22 | 1.82B | -63% | -63% | — | — | -1.20 | 0.58 | 0.40 | -1.52 | -0.17 | 1.94 | 35.14% | 8.07% | -33.51% | -39.29% | 6.99% | -15.68% | 0.01 | 2.11 | 2.76 | 1.13 | 0.62 | 72320.00% | -275.00% | -4068.00% | 8.49% | 0.24 | 2.96% | 9.32% | -11.20% | 217.29% | 3.54 | 8.37 | 0.29 | 0.46 |
| XRAY | DENTSPLY SIRONA Inc. | $14.68 | 2.93B | +40% | -61% | — | — | -4.77 | 2.13 | 0.78 | -107.57 | — | -3.65 | 50.00% | 6.85% | -16.25% | -36.44% | 6.83% | -10.70% | 1.81 | 2.86 | 1.51 | 0.76 | -45.54 | -3304.00% | -298.00% | -6299.00% | 3.64% | 0.17 | 2.82% | 4.49% | -21.40% | 4.49% | 19.64 | 47.58 | 1.34 | 1.00 |
About Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- CEO
- Thomas J. Appio
- Employees
- 20.7K
- Beta
- 0.38
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.88 ÷ $5.65) − 1 = +74.87% (DCF, example).